Novartis’s Cosentyx failed to beat a placebo in a Phase 3 clinical trial in giant cell arteritis. The antibody drug was being developed as an alternative to Roche and AbbVie drugs whose approved uses include treating this autoimmune disorder affecting blood vessels. The post Blockbuster Novartis Drug Fails Key Test Hoped to Expand Its Use…
To scale clinical AI, vendors must design tools that feel natural and personalized to each doctor — otherwise, clinicians won’t use them, said Heidi Health CEO Tom Kelly. In the crowded AI scribe market, he believes that clinician adoption rates, not flashy integration or deployment speeds, are the true measure of success. The post How…
AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a heavily pretreated patient population and a favorable safety profile. The post AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma appeared first…
On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025. The post Scholar Rock Scores $300M for Regulatory Filings & Launch Plans for Neuromuscular…
The answer appears to be ‘yes’ according a recent paper written by Uchechukwu Love Anyaduba, Oluwatosin Qawiyy Orababa, Zion Faye, Nazia Rashid, Gregory Reardon and myself. The abstract is below: BackgroundCancer trials increasingly use surrogate endpoints, but it is unclear how well recurrence-free survival (RFS) or disease-free survival (DFS) specifically predict overall survival (OS) in…
Saniona’s drug candidate could expand Jazz Pharmaceuticals portfolio in epilepsy. But this preclinical small molecule will need to show advantages in safety and efficacy to compete with Biohaven Pharmaceuticals and Xenon Pharmaceuticals, each with clinical-stage drugs that hit the same epilepsy target. The post Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective…
Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined. The post Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s appeared first on MedCity…
Closing cancer health equity gaps requires medical breakthroughs made possible by new funding approaches. The post The Funding Model for Cancer Innovation is Broken — We Can Fix It appeared first on MedCity News.
This may be the best comeback performance of all time. Not only did Lindsey Vonn come out of retirement to race a World Cup downhill at age 40 but she placed 6th and did it on an artificial knee! Here’s the details on the surgery but first watch her performance and just look how happy…